Related Experiment Videos
[New treatments for heart failure?].
1Clínica de Insuficiencia Cardíaca, Instituto Nacional de Cardiología Ignacio Chávez, INCICH, Juan Badiano No. 1, Col. Sección XVI, Tlalpan, 14080 México, D.F.
Archivos De Cardiologia De Mexico
|September 12, 2003
Summary
New heart failure treatments are being explored. Arginine vasopressin receptor (AVP) blockade shows promise in humans, while matrix metalloproteinase (MMP) inhibitors are still in early, debated stages.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Context:
- Chronic heart failure (CHF) treatment requires novel strategies beyond current therapies.
- Existing treatments like endothelin-1 (ET-1), tumor necrosis factor-alpha (TNF-alpha), angiotensin-converting enzyme (ACE), and neutral endopeptidase (NE) inhibition offer limited benefits.
- The evaluation of alternative therapeutic targets is crucial for improving CHF outcomes.
Purpose:
- To review current therapeutic concepts for chronic heart failure.
- To discuss the potential of arginine vasopressin receptor (AVP) blockade and selective matrix metalloproteinase (MMP) inhibition.
- To assess the clinical and preclinical status of these emerging treatment strategies.
Summary:
- Arginine vasopressin receptor (AVP) blockade has yielded encouraging results in human trials for chronic heart failure.
- Selective inhibition of matrix metalloproteinases (MMPs) is currently in preclinical experimental phases.
- The efficacy and application of MMP inhibitors in heart failure remain controversial and require further investigation.
Impact:
- Encouraging human data for AVP blockade suggests a potential new therapeutic avenue for chronic heart failure.
- The preclinical and controversial status of MMP inhibitors highlights the need for continued research and development.
- This review provides insights into the evolving landscape of heart failure pharmacotherapy, guiding future research and clinical evaluation.